Mechanism

Delta sleep-inducing peptide (DSIP) is a naturally occurring neuropeptide first isolated in relation to sleep research. Its precise receptor targets and mechanism in humans remain poorly characterized.

Research summary

Evidence is largely older and preclinical, with small and inconsistent human studies on sleep and stress. It is not an FDA-approved drug, and robust modern clinical data are lacking. Claims should be read against that evidence gap. In July 2026 an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted 6-7, with one abstention, to recommend against adding this compound (referenced in the FDA agenda as emideltide) to the 503A bulk-compounding list, citing a lack of safety and efficacy data. It remains outside the regulated compounding pathway.

Reported side effects

Controlled human safety data are limited, so the side-effect and long-term safety profile is largely unknown. Sourcing and purity are recurring quality concerns.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

DSIP sleep and neuroendocrine research overview · peer-reviewed review article (1984)older, largely preclinical evidence; search PubMed for delta sleep-inducing peptide
Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status

TrackPep slouží ke sledování záznamů. Zaznamenává, co zadáte, a nikdy nedoporučuje ani nevypočítává množství.